Michael Drummond

Summary

Affiliation: University of York
Country: UK

Publications

  1. doi request reprint Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves?
    Michael F Drummond
    University of York, York, UK
    Int J Technol Assess Health Care 24:146-50. 2008
  2. pmc Economics methods in Cochrane systematic reviews of health promotion and public health related interventions
    Ian Shemilt
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    BMC Med Res Methodol 6:55. 2006
  3. ncbi request reprint Economic evaluation
    M F Drummond
    Centre for Health Economics, University of York, Heslington, York YO10 5DD, The United Kingdom
    Singapore Med J 47:456-61; quiz 462. 2006
  4. ncbi request reprint Health technology assessment in the United Kingdom
    Michael Drummond
    Centre for Health Economics, University of York, Heslington, York YO10 5DD, United Kingdom
    Int J Technol Assess Health Care 25:178-81. 2009
  5. ncbi request reprint NICE: a nightmare worth having?
    Michael Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Health Econ Policy Law 2:203-8; discussion 217-21. 2007
  6. doi request reprint Key principles for the improved conduct of health technology assessments for resource allocation decisions
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008
  7. doi request reprint Can NICE be nicer? In a world of budget constraints there are no easy solutions
    Michael Drummond
    Centre for Health Economics, University of York, York, UK
    Value Health 12:634-6. 2009
  8. pmc Pharmacoeconomics: friend or foe?
    M Drummond
    Centre for Health Economics, Alcuin A Block, University of York, Heslington, York YO10 5DD, UK
    Ann Rheum Dis 65:iii44-7. 2006
  9. ncbi request reprint Assessing the economic challenges posed by orphan drugs
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 23:36-42. 2007
  10. ncbi request reprint [High class of Swedish health economics seen from the international point of view. Continuous progress demands economical and political support according to an evaluation]
    Michael Drummond
    Centre for Health Economics, University of York, Storbritannien
    Lakartidningen 103:3696-7. 2006

Collaborators

Detail Information

Publications77

  1. doi request reprint Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves?
    Michael F Drummond
    University of York, York, UK
    Int J Technol Assess Health Care 24:146-50. 2008
    ..The objective of this study was to assess the extent to which the systematic review of the clinical literature informs the economic evaluation in NICE technology appraisals...
  2. pmc Economics methods in Cochrane systematic reviews of health promotion and public health related interventions
    Ian Shemilt
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    BMC Med Res Methodol 6:55. 2006
    ....
  3. ncbi request reprint Economic evaluation
    M F Drummond
    Centre for Health Economics, University of York, Heslington, York YO10 5DD, The United Kingdom
    Singapore Med J 47:456-61; quiz 462. 2006
    ..Additionally, an analytical critique of economic evaluations undertaken in Singapore is provided, and the prospects for economic evaluation in the future are discussed...
  4. ncbi request reprint Health technology assessment in the United Kingdom
    Michael Drummond
    Centre for Health Economics, University of York, Heslington, York YO10 5DD, United Kingdom
    Int J Technol Assess Health Care 25:178-81. 2009
    ..The aim of this study was to describe generally the development and present situation with health technology assessment (HTA) in the United Kingdom...
  5. ncbi request reprint NICE: a nightmare worth having?
    Michael Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Health Econ Policy Law 2:203-8; discussion 217-21. 2007
  6. doi request reprint Key principles for the improved conduct of health technology assessments for resource allocation decisions
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008
    ..The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making."..
  7. doi request reprint Can NICE be nicer? In a world of budget constraints there are no easy solutions
    Michael Drummond
    Centre for Health Economics, University of York, York, UK
    Value Health 12:634-6. 2009
    ..This counterpoint article discusses the key issues in more detail and suggests ways in which NICE might improve, given the difficulties in making resource allocation decisions under a budget constraint...
  8. pmc Pharmacoeconomics: friend or foe?
    M Drummond
    Centre for Health Economics, Alcuin A Block, University of York, Heslington, York YO10 5DD, UK
    Ann Rheum Dis 65:iii44-7. 2006
    ....
  9. ncbi request reprint Assessing the economic challenges posed by orphan drugs
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 23:36-42. 2007
    ....
  10. ncbi request reprint [High class of Swedish health economics seen from the international point of view. Continuous progress demands economical and political support according to an evaluation]
    Michael Drummond
    Centre for Health Economics, University of York, Storbritannien
    Lakartidningen 103:3696-7. 2006
  11. ncbi request reprint European perspective on the costs and cost-effectiveness of cancer therapies
    Michael F Drummond
    Centre for Health Economics, University of York, York, United Kingdom
    J Clin Oncol 25:191-5. 2007
    ....
  12. doi request reprint Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report
    Michael Drummond
    Centre for Health Economics, University of York, York, UK
    Value Health 12:409-18. 2009
    ....
  13. pmc Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
    Michael Drummond
    Centre for Health Economics, Alcuin A Block, University of York, Heslington, York, YO10 5DD, UK
    Eur J Health Econ 12:263-71. 2011
    ..However, given the relatively higher costs of conducting HTAs, the most efficient approach might be a combination of both policies...
  14. doi request reprint Guidelines for completing the EURONHEED transferability information checklists
    John Nixon
    Department of Economics and Related Studies, University of York, York, YO10 5DD, UK
    Eur J Health Econ 10:157-65. 2009
    ..We also briefly discuss associated issues such as weighting of items in the checklists and give further clarifications regarding what we consider the most appropriate applications of the checklists to be...
  15. doi request reprint Can we reliably benchmark health technology assessment organizations?
    Michael Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 28:159-65. 2012
    ..Given this greater emphasis on the use of HTA, it is important to develop standards of good practice and to benchmark the various HTA organizations against these standards...
  16. ncbi request reprint Common methodological flaws in economic evaluations
    Michael Drummond
    Centre for Health Economics, University of York, York, United Kingdom
    Med Care 43:5-14. 2005
    ..In each case examples are given from the literature and guidance is offered on how to detect flaws in economic evaluations...
  17. ncbi request reprint Moving beyond the drug budget silo mentality in Europe
    Michael Drummond
    Centre for Health Economics, University of York, York, UK
    Value Health 6:S74-7. 2003
  18. doi request reprint Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Anne Mason
    Centre for Health Economics, University of York, York, United Kingdom
    J Clin Oncol 28:3234-8. 2010
    ..Coverage decisions that consider cost effectiveness may lead to restrictions in access...
  19. ncbi request reprint Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies
    Michael Drummond
    University of York, North Yorkshire, UK
    Int J Technol Assess Health Care 21:165-71. 2005
    ..However, the sharing of the results from HTAs raises questions about their generalizability; namely, are the results of an HTA undertaken in one country relevant to another?..
  20. ncbi request reprint The usefulness of the NHS Economic Evaluation Database to researchers undertaking technology assessment reviews
    John Nixon
    University of York, Heslington, UK
    Int J Technol Assess Health Care 20:249-57. 2004
    ..This study reports the findings and implications of a survey to explore the usefulness of the National Health Service Economic Evaluation Database (NHS EED) within this process...
  21. ncbi request reprint The European Network of Health Economic Evaluation Databases (EURO NHEED) Project
    John Nixon
    Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK
    Eur J Health Econ 5:183-7. 2004
    ..The project will therefore advance the state of the art in collecting, summarising, critiquing and disseminating economic evaluations of healthcare conducted within Europe...
  22. ncbi request reprint Influencing prescribing in English primary care: the views of primary care organisations
    Anne Mason
    Centre for Health Economics, University of York, York, UK
    J Health Serv Res Policy 9:153-8. 2004
    ..The purpose of this study was to identify the approaches to improve primary care prescribing by primary care organisations (PCOs) in the National Health Service (NHS) in England...
  23. ncbi request reprint Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making
    Michael Drummond
    University of York, York, UK
    Value Health 6:407-16. 2003
    ....
  24. doi request reprint Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations
    Helen Weatherly
    Centre for Health Economics, University of York, United Kingdom
    Health Policy 93:85-92. 2009
    ..In contrast, the economic evaluation of public health interventions raises additional methodological challenges. The paper identifies these challenges and provides suggestions for overcoming them...
  25. ncbi request reprint Towards a reference case for use in future economic evaluations of interventions in osteoarthritis
    Michael Drummond
    Centre for Health Economics, University of York, York, UK
    J Rheumatol Suppl 68:26-30. 2003
  26. ncbi request reprint Prioritizing investments in health: can we assess potential value for money?
    Michael Drummond
    Centre for Health Economics, University of York, Heslington, York, YO10 5DD, United Kingdom
    J Rheumatol Suppl 68:19-20. 2003
  27. ncbi request reprint An evaluation of Swedish health economics research
    Michael Drummond
    Centre for Health Economics, University of York, UK
    Scand J Public Health Suppl 68:5-43. 2006
  28. ncbi request reprint Using economic evidence to support decision making: a case study of assertive community treatment within the UK National Service Framework for Mental Health
    John Nixon
    NHS Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK
    Appl Health Econ Health Policy 1:179-90. 2002
    ....
  29. ncbi request reprint In the land of blind decision making, is one-eyed economics the king?
    Michael Drummond
    Centre for Health Economics, University of York, United Kingdom
    Appl Health Econ Health Policy 2:73-6. 2003
  30. ncbi request reprint Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness?
    Michael Drummond
    Centre for Health Economics, University of York, York, UK
    Appl Health Econ Health Policy 1:53-4. 2002
  31. ncbi request reprint A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines
    J Mason
    Medicines Evaluation Group Centre for Health Economics, University of York, Heslington, UK
    Health Policy 47:37-52. 1999
    ..The implications of this method are discussed, guidance offered for economists new to guideline development and future areas of work identified...
  32. ncbi request reprint A randomized trial of Evidence-based OutReach (EBOR): rationale and design
    N Freemantle
    Centre for Health Economics, University of York, Heslington, United Kingdom
    Control Clin Trials 20:479-92. 1999
    ..The study design addresses important factors that may influence the effectiveness of the intervention, such as the pharmacist who delivers the messages, the health authority in which practices are located, and the size of a practice...
  33. ncbi request reprint Is disease management relevant in Europe: some evidence from the United Kingdom
    A Mason
    Centre for Health Economics, University of York, Heslington, UK
    Health Policy 48:69-77. 1999
    ..The major perceived barrier to an increase in disease management was NHS suspicion of pharmaceutical companies (86% of all respondents), with the difficulty in drawing up contracts coming a close second (79%)...
  34. ncbi request reprint Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group
    M J Sculpher
    Centre for Health Economics, University of York, Helsington, York, YO10 5DD, UK
    Eur J Heart Fail 2:447-54. 2000
    ..A cost-effectiveness analysis of high and low doses of the angiotensin-converting enzyme (ACE) inhibitor lisinopril in the treatment of chronic heart failure...
  35. ncbi request reprint Introducing economic and quality of life measurements into clinical studies
    M Drummond
    Centre for Health Economics, University of York, UK
    Ann Med 33:344-9. 2001
    ..In particular, recommendations are given for choosing the range of quality of life instruments, sample size calculations for quality of life measurement and the measurement of quality of life in multinational studies...
  36. ncbi request reprint The effectiveness and cost-effectiveness of respite for caregivers of frail older people
    Anne Mason
    Centre for Health Economics, University of York, York, United Kingdom
    J Am Geriatr Soc 55:290-9. 2007
    ..Given the increasing numbers of frail elderly people and the lack of up-to-date, good-quality evidence for all types of respite care, better-quality evidence is urgently needed to inform current policy and practice...
  37. ncbi request reprint A rational framework for decision making by the National Institute For Clinical Excellence (NICE)
    Karl Claxton
    Department of Economics and Related Studies, University of York, Heslington, York, UK
    Lancet 360:711-5. 2002
    ..Additionally, the analysis can be used to aid the efficient design of research. We discuss the implications of adoption of this new framework for regulatory and reimbursement decisions...
  38. doi request reprint Assessing the added value of health technologies: reconciling different perspectives
    Michael Drummond
    Centre for Health Economics, University of York, York, UK
    Value Health 16:S7-13. 2013
    ..These include rethinking the notion of social value (on the part of payers), aligning manufacturers' research more closely with societal objectives, and increasing patient participation in health technology assessment...
  39. ncbi request reprint A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus france
    Michael Drummond
    Centre for Health Economics, University of York, Alcuin A Block, Heslington, York, YO10 5DD, UK
    Pharmacoeconomics 32:509-20. 2014
    ..This assessment then influences price negotiations. The objective of this paper is to assess the pros and cons of each approach, both in terms of the assessments they produce and the efficiency and practical feasibility of the process...
  40. ncbi request reprint Orphan drugs policies: a suitable case for treatment
    Michael Drummond
    Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK
    Eur J Health Econ 15:335-40. 2014
    ..Those funding health care find that most orphan drugs do not justify funding based on standard value for money criteria, yet that they face political problems if they fail to provide funding for therapy...
  41. ncbi request reprint Do we fully understand the economic value of vaccines?
    Michael Drummond
    Centre for Health Economics, University of York, UK
    Vaccine 25:5945-57. 2007
    ..In each case the evidence is considered alongside existing vaccination policies in the major developed countries. The paper also highlights areas where traditional economic evaluations may not adequately reflect the value of vaccines...
  42. ncbi request reprint Economic evaluation of drugs in peripheral vascular disease and stroke
    M Drummond
    Centre for Health Economics, University of York, England
    J Cardiovasc Pharmacol 23:S4-7. 1994
    ..A study in the U.K. found that arterial construction would cost around pounds 7,750 per person (1989 prices) and amputation around pounds 11,000 per person.(ABSTRACT TRUNCATED AT 250 WORDS)..
  43. ncbi request reprint A systematic review of the effectiveness and cost-effectiveness of different models of community-based respite care for frail older people and their carers
    A Mason
    Centre for Health Economics, University of York, UK
    Health Technol Assess 11:1-157, iii. 2007
    ..Where data permitted, subgroups of carers and care recipients, for whom respite care is particularly effective or cost-effective, were to be identified...
  44. ncbi request reprint Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation
    J Wilby
    Centre for Reviews and Dissemination, University of York, UK
    Health Technol Assess 9:1-157, iii-iv. 2005
    ..To examine the clinical effectiveness, tolerability and cost-effectiveness of gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), tiagabine (TGB), topiramate (TPM) and vigabatrin (VGB) for epilepsy in adults...
  45. ncbi request reprint The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial
    J Mason
    Centre for Health Economics, University of York, York, UK
    Aliment Pharmacol Ther 16:559-68. 2002
    ..pylori screening and treatment over 2 years in a randomized controlled trial and have incorporated the results into an economic model exploring the impact of H. pylori eradication on peptic ulcer disease and gastric cancer...
  46. ncbi request reprint Stapled haemorrhoidectomy (haemorrhoidopexy) for the treatment of haemorrhoids: a systematic review and economic evaluation
    J Burch
    Centre for Reviews and Dissemination, University of York, UK
    Health Technol Assess 12:iii-iv, ix-x, 1-193. 2008
    ..To determine the safety, clinical effectiveness and cost-effectiveness of circular stapled haemorrhoidopexy (SH) for the treatment of haemorrhoids...
  47. ncbi request reprint A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents
    S King
    Centre for Reviews and Dissemination, University of York, UK
    Health Technol Assess 10:iii-iv, xiii-146. 2006
    ....
  48. ncbi request reprint Evidence for coverage decisions: the need for a reality check
    Michael Drummond
    Value Health 10:321. 2007
  49. ncbi request reprint Are the best available clinical effectiveness data used in economic evaluations of drug therapies?
    Barbara Hanratty
    Division of Public Health, University of Liverpool, Liverpool, UK
    J Health Serv Res Policy 12:138-41. 2007
    ..This study aimed to determine whether the authors of economic evaluations use the best available evidence for clinical effectiveness...
  50. ncbi request reprint Health care resource use and stroke outcome. Multinational comparisons within the GAIN International trial
    Kjell Asplund
    Department of Medicine, University Hospital, Umea, Sweden
    Int J Technol Assess Health Care 19:267-77. 2003
    ....
  51. ncbi request reprint Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?
    Naoki Ikegami
    Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan
    Pharmacoeconomics 20:1-7. 2002
    ..However, small but encouraging steps are now being taken towards the introduction of economic evaluations in Japanese medicine...
  52. doi request reprint Economic evaluation of health interventions
    Michael Drummond
    BMJ 337:a1204. 2008
  53. ncbi request reprint Using evidence in the development of local health policies. Some evidence from the United Kingdom
    Helen Weatherly
    University of York
    Int J Technol Assess Health Care 18:771-81. 2002
    ..This paper explores the use of evidence, focusing on economic evidence in particular, in the development of local health policies through an in-depth study of Health Improvement Programmes (HImPs) in England...
  54. ncbi request reprint Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts?
    Sally C Stearns
    Med Care 41:1-3. 2003
  55. ncbi request reprint Information barriers to the implementation of economic evaluations in Japan
    Shuzo Nishimura
    Faculty of Economics, Kyoto University, Kyoto, Japan
    Pharmacoeconomics 20:9-15. 2002
    ..To overcome these information barriers in Japan, progress may be aided by the adoption of approaches used in other countries for data collection and guideline development...
  56. ncbi request reprint Best practice in undertaking and reporting health technology assessments. Working group 4 report
    Marcial Velasco
    Technische Universitat Berlin, Germany
    Int J Technol Assess Health Care 18:361-422. 2002
  57. ncbi request reprint Re: Hutton J, Brown R. Use of economic evaluation in decision-making: what needs to change? (Editorial) Value Health 2002;5:65-6
    Chritiane Hoffmann
    Value Health 5:114. 2002
  58. ncbi request reprint A research agenda for economic evaluation of substance abuse services
    Michael T French
    Department of Sociology, University of Miami, Coral Gables, FL 33124 2030, USA
    J Subst Abuse Treat 29:125-37. 2005
    ....
  59. ncbi request reprint Technology assessment in the German context
    Michael Drummond
    Eur J Health Econ 8:S3. 2007
  60. ncbi request reprint Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model
    Neil Hawkins
    Med Decis Making 25:493-510. 2005
    ..These include the methods used to deal with the absence of head-to-head trial data and the need to reflect time dependency in Markov transition probabilities...
  61. ncbi request reprint Taking clinical trials to task
    Michael Drummond
    Value Health 8:517-8. 2005
  62. ncbi request reprint Can economic evaluations be made more transferable?
    Stephanie Boulenger
    Collège des Economistes de la Santé, Paris, France
    Eur J Health Econ 6:334-46. 2005
    ..Further research is in progress on producing a weighted version of the checklist...
  63. ncbi request reprint The desirability and feasibility of economic studies of drugs post-launch
    Michael Drummond
    Eur J Health Econ 7:5-6. 2006
  64. ncbi request reprint The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK
    Marco Barbieri
    Universitat Pompeu Fabra, Barcelona, Spain
    Pharmacoeconomics 23:607-18. 2005
    ....
  65. ncbi request reprint Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability
    Marco Barbieri
    Innovus Research UK Ltd High Wycombe, UK
    Value Health 8:10-23. 2005
    ..There has been, however, little study of the causes of variation, whether differences in study results among countries are systematic, or whether they are important for decision making...
  66. ncbi request reprint The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project
    Gerard De Pouvourville
    Collège des Economistes, Paris, France
    Pharmacoeconomics 23:113-20. 2005
    ....
  67. ncbi request reprint Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia
    John R Cook
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Pharmacoeconomics 22:37-48. 2004
    ....
  68. ncbi request reprint Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study
    Andrea Bracco
    Novartis Pharma AG, Basel, Switzerland
    Value Health 10:238-46. 2007
    ..The aim of this study was to assess, from a payer perspective, the cost-effectiveness of tegaserod in the treatment of IBS patients, based on the TEgaserod in NORdic region (TENOR) trial data...
  69. ncbi request reprint The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model
    Samuel Aballea
    i3 Innovus, Uxbridge, UK
    Value Health 10:98-116. 2007
    ..To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy...
  70. ncbi request reprint Regulatory issues and economic efficiency
    Maria E Suarez-Almazor
    Baylor College of Medicine, Houston Veteran Affairs Medical Center, Houston, Texas, USA
    J Rheumatol Suppl 68:5-7. 2003
  71. ncbi request reprint Issues for countries considering introducing the "fourth hurdle": the case of Hungary
    Laszlo Gulacsi
    Department of Public Policy and Management, Budapest University of Economic Sciences and Public Administration, Hungary
    Int J Technol Assess Health Care 20:337-41. 2004
    ..e., requirement of effectiveness and cost-effectiveness data for drug coverage policy decisions) in Hungary, describes the legal background and seeks to address some of the most important questions in this field...
  72. ncbi request reprint Economic endpoints in clinical trials
    John Cook
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Stat Methods Med Res 13:157-76. 2004
    ..Alternative approaches in the analysis of resource utilization, cost and cost-effectiveness are also presented. Finally, several of the analytic approaches are applied to actual data from a clinical trial...
  73. ncbi request reprint Better analysis for better decisions: has pharmacoeconomics come of age?
    Michael Drummond
    Pharmacoeconomics 24:107-8. 2006
  74. ncbi request reprint A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine
    Nicholas Wells
    Outcomes Research, Pfizer Global Research and Development, Sandwich, UK
    Value Health 6:438-47. 2003
    ..This article explores the application of cost-effectiveness analysis in a comparison of eletriptan and sumatriptan in the acute treatment of migraine...
  75. pmc New BMJ policy on economic evaluations. Response of NHS Economic Evaluation Database Research Team
    Dawn Craig
    BMJ 326:445; author reply 445. 2003
  76. ncbi request reprint Assessing the appropriateness of combining economic data from multinational clinical trials
    John R Cook
    Health Economic Statistics, Merck Research Laboratories, UN A102, West Point, PA 19486, U S A
    Stat Med 22:1955-76. 2003
    ..We explore the analytic issues by further analysing data from the Scandinavian Simvastatin Survival Study (4S)...
  77. ncbi request reprint OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis
    Sherine Gabriel
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Rheumatol 30:886-90. 2003
    ..Through these efforts, the OMERACT Economics Working Group aims to expedite and enhance the conduct and dissemination of methodological research in economic analyses in the rheumatic diseases...